PDE-5 Inhibition and Sexual Response: Pharmacological Mechanisms and Clinical Outcomes

Annual Review of Sex Research

Volumn 8, Issue , 2002, Pages 36-88

  Rosen, Raymond C ^a   McKenna, Kevin E ^b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Erectile dysfunction; Erection; Female sexual dysfunction; Penis; Phosphodiesterase type 5 inhibitor; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

CARBOLINE DERIVATIVE; CYCLIC GMP; IMIDAZOLE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; SILDENAFIL; SULFONE; TADALAFIL; TRIAZINE DERIVATIVE; VARDENAFIL; VASODILATOR AGENT;

CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; IMPOTENCE; MALE; METABOLISM; PENIS ERECTION; PSYCHOLOGICAL ASPECT; REVIEW; SMOOTH MUSCLE; TREATMENT OUTCOME;

CARBOLINES; CLINICAL TRIALS; CYCLIC GMP; FEMALE; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; MUSCLE, SMOOTH; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SULFONES; TREATMENT OUTCOME; TRIAZINES; VASODILATOR AGENTS;

EID: 0037812474     PISSN: 10532528     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (160)

1. Abdel-Hamid, I. A., El Naggar, E. A., & El Gilany, A. H. (2001). Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. International Journal of Impotence Research, 13(1), 41-45.
2. Althof, S. E., Levine, S. B., & Corty, E. W. (1995). A double-blind, crossover trial of clomipramine for rapid ejaculation in 15 couples. Journal of Clinical Psychiatry, 56, 402-407.
3. Althof, S. E., & Turner, L. A. (1992). Self-injection therapy and external vacuum devices in the treatment of erectile dysfunction. In R. C. Rosen & S. R. Leiblum (Eds.), Erectile disorders: Assessment and treatment (pp. 283-312) New York: Guilford.
4. Andersson, K-E., Hedlund, P., & Alm, P. (2000). Sympathetic pathways and adrenergic innervation of the penis. International Journal of Impotence Research, 12, S5-S12.
5. Andersson, K. E., & Wagner, G. (1995). The physiology of penile erection. Physiological Reviews, 75, 191-236.
6. Anonymous. (2001). Caution about club drugs and Viagra. AIDS Patient Care & Studies, 15, 598.
7. Aoyagi, T., Hayakawa, K., Miyaji, K., Ishikawa, H., & Hata, M. (1999). Sildenafil induced priapism. Bulletin of Tokyo Dental College, 40, 215-217.
8. Arruda-Olsen, A. M., Mahoney, D. W., Nehra, A., Leckel, M., & Pellikka, P. A. (2002). Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: A randomized crossover trial. Journal of the American Medical Association, 287, 766-767.
9. Araujo, A. B., Johannes, C. B., Feldman, H. A., Derby, C. A., & McKinlay, J. B. (2000). Relation between psychosocial risk factors and incident erectile dysfunction: Prospective results from the Massachusetts Male Aging Study. American Journal of Epidemiology, 152, 533-541.
10. Ashton, A. K., & Bennett, R. G. (1999), Sildenafil treatment of serotonin reuptake inhibitor-induced sexual dysfunction. Journal of Clinical Psychiatry, 60, 194-195.
11. Aversa, A., Mazzili, F., Rossi, T., Delfino, M., Isidori, A. M., & Fabbri, A. (2000). Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males. Human Reproduction, 15, 131-134.
12. Ballard, S. A., Gingell, C. J., Tang, K., Turner, L. A., Price, M. E., & Naylor, A. M. (1998). Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. Journal of Urology, 159, 2164-2171.
13. Bancroft, J. (2002), The medicalization of female sexual dysfunction: The need for caution. Archives of Sexual Behavior, 31, 451-456.
14. Basson, R., Berman, J., Burnett, A., Derogatis, L., Ferguson, D., Fourcroy, J., et al. (2000). Report of the International Consensus Development Conference on Female Sexual Dysfunction: Definitions and classifications. Journal of Urology, 163, 888-893.
15. Basson, R., McInnes, R., Smith, M. D., Hodgson, G., & Koppiker, N. (2002). Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. Journal of Women's Health and Gender-Based Medicine, 11, 367-377.
16. Beavo, J. A. (1995). Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiology Reviews, 75, 725-748.
17. Berman, J. R., Berman, L. A., Lin, H., Flaherty, E., Lahey, N., Goldstein, I., & Cantey-Kiser, J. (2001). Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder. Journal of Sex and Marital Therapy, 27, 411-420.
18. Bischoff, E. (2001). Rabbits as models for impotence research. International Journal of Impotence Research, 13, 146-148.
19. Bischoff, E., Niewoehner, U., Haning, H., Es Sayed, M., Schenke, T., & Schlemmer, K. H. (2001). The oral efficacy of vardenafil hydrochloride for inducing penile erection in a conscious rabbit model. Journal of Urology, 165, 1316-1318.
20. Bischoff, E., & Schneider, K. (2001). A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection. International Journal of Impotence Research, 13, 230-235.
21. Blander, D. S., Sanchez-Ortiz, R. F., Wein, A. J., & Broderick, G. A. (2000). Efficacy of sildenafil in erectile dysfunction after radical prostatectomy. International Journal of Impotence Research, 12, 165-168.
22. Blanker, M. H., Bohnen, A. M., Groeneveld, F. P., Bernsen, R. M., Prins, A., Thomas, S., & Bosch, J. L. (2001). Correlates for erectile and ejaculatory dysfunction in older Dutch men: A community-based study. Journal of American Geriatric Society, 49, 436-442.
23. Boolell, M., Allen, M. J., Ballard, S. A., Gepi-Attee, S., Muirhead, G. J., Naylor, A. M., et al. (1996). Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. International Journal of Impotence Research, 8, 47-52.
24. Boolell, M., Gepi-Attee, S., Gingell, J. C., & Allen, M. J. (1996). Sildenafil: A novel effective oral therapy for male erectile dysfunction. British Journal of Urology, 78, 257-261.
25. Bortolotti, M., Mari, C., Giovannini, M., Pinna, S., Miglioli, M., & Pandolfo, N. (2001). Effects of sildenafil on esophageal motility of normal subjects. Digestive Diseases Sciences, 46, 2301-2306.
26. Bortolotti, M., Mari, C., Lopilato, C., Porrazo, G. & Miglioli, M. (2000). Effects of sildenafil on eaophageal motility of patients with idiopathic achalasia. Gastroenterology, 118, 253-257.
27. Boulton, A. J., Selam, J. L., Sweeney, M., & Ziegler, D. (2001). Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia, 44, 1296-1301.
28. Braun, M., Wassmer, G., Klotz, T., Reifenrath, B., Mathers, M., & Engelmann, U. (2000). Epidemiology of erectile dysfunction: Results of the "Cologne Male Survey." International Journal of Impotence Research, 12, 305-311.
29. Brindley, G. (1983). Cavernosal alpha-blockage: A new technique for investigating and treating erectile impotence. British Journal of Psychiatry, 143, 332-337.
30. Brock, G., Iglesias, J., Toulouse, K., Ferguson, K. M., Pullman, W. E., & Anglin, G. (2001, September 30-October 3). Efficacy and safety of IC351 treatment for ED. Poster presentation at the 4th Congress of the European Society for Sexual and Impotence Research, Rome, Italy.
31. Buffum, J. (1982). Pharmacosexology: The effects of drugs on sexual function. Journal of Psychoactive Drugs, 14, 5-44.
32. Burnett, A. L., Calvin, D. C., Silver, R. I., Peppas, D. S., & Docimo, S. G. (1997). Immunohistochemical description of nitric oxide synthase isoforms in human clitoris. Journal of Urology, 158, 75-78.
33. Campbell, S. F. (2000). Science, art and drug discovery: A personal perspective. Clinical Science, 99, 255-260.
34. Cappelleri, J. C., Rosen, R. C., Smith, M. D., Mishra, A., & Osterloh, I. H. (1999). Diagnostic evaluation of the erectile function domain on the International Index of Erectile Function. Urology, 64, 346-351.
35. Caruso, S., Intelisano, G., Lupo, L., & Agnello, C. (2001). Premenopausal women affected by sexual arousal disorder treated with sildenafil: A double-blind, cross-over, placebo-controlled study. Bjogesta, 108, 623-628.
36. Carvajal, J. A., Germain, A. M., Huidobro-Toro, J. P., & Weiner, C. P. (2000). Molecular mechanism of cGMP mediated smooth muscle relaxation. Journal of Cellular Physiology, 184, 409-420.
37. Cellek, S., & Moncada, S. (1998). Nitrergic neurotransmission mediates the nonadrenergic noncholinergic responses in the clitoral corpus cavernosum of the rabbit. British Journal of Pharmacology, 125, 1627-1629.
38. Charan, N. B. (2001). Does sildenafil also improve breathing? Chest, 120, 305-306.
39. Chen, J., Mabjeesh, N. J., Greenstein, A., Nadu, A., & Matzkin, H. (2001). Clinical efficacy of sildenafil in patients on chronic dialysis. Journal of Urology, 165, 819-821.
40. Christ, G. J. (1997). The "syncytial tissue triad": A model for understanding how gap junctions participate in the local control of penile erections. World Journal of Urology, 13, 36-44.
41. Christ, G. J., Wang, H.Z., Venkateswarlu, K., Zhao, W., & Day, N. S. (1999). Ion channels and gap junctions: Their role in erectile physiology, dysfunction and future therapy. Molecular Urology 3, 61-74.
42. Christiansen, E., and the Multicentre Study Group; Hodges, M., Hollingshead, M., Kirkpatrick, J., Dickinson, S., Osterloh, I. (1996). Sildenafil (Viagra™) a new oral treatment for erectile dysfunction (ED): Results of a 16-week open dose escalation study [Abstract]. International Journal of Impotence Research, 8, 147.
43. Conti, C. R., Pepine, C. J., & Sweeney, M. (1999). Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. American Journal of Cardiology, 83, 29C-34C.
44. Corbin, J. D., & Francis, S. H. (1999). Cyclic GMP phosphodiesterase-5: Target of sildenafil. Journal of Biological Chemistry, 274, 13729-13732.
45. Crenshaw, T. L., & Goldberg, J. P. (1996). Sexual pharmacology: Drugs that affect sexual function. New York: Norton Press.
46. D'Amati, G., diGioia, C. R., Bologna, M., Giordano, D., Giorgi, M., Dolci, S., & Jannini, E. A. (2002). Type 5 phosphodiesterase expression in the human vagina. Urology, 60, 191195.
47. DeBusk, R., Drory, Y., Goldstein, I., Jackson, G., Kaul, S., Kimmel, S. E., et al. (2000). Management of sexual dysfunction in patients with cardiovascular disease: Recommendations of The Princeton Consensus Panel. American Journal of Cardiology, 86, 175-181.
48. De Groat, W. C., & Steers, W. D. (1990). Autonomic regulation of the urinary bladder and sexual organs. In A. D. Loewy & K. M. Spyer (Eds.), Central regulation of autonomic functions (pp. 310-333). New York: Oxford University Press.
49. Dinsmore, W. W., Hodges, M., Hargreaves, C., Osterloh, I. H., Smith, M. D., & Rosen, R. C. (1999). Sildenafil Citrate (Viagra) in erectile dysfunction: Near normalization in men with broad spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology, 53, 800-805.
50. Dunn, K. M., Croft, P. R., & Hackett, G. I. (1998). Sexual problems: A study of the prevalence and need for health care in the general population. Family Practice, 15, 519-524.
51. El-Galley, R., Rutland, H., Talic, R., Keane, T., & Clark, H. (2001). Long-term efficacy of sildenafil and tachyphylaxis effect. Journal of Urology 166, 927-931.
52. Fava, M., Rankin, M. A., Alpert, J. E., Niernberg, & Worthington, J. (1998). An open trial of oral sildenafil in antidepressant-induced sexual dysfunction. Psychotherapy and Psychosomatics 67, 328-331.
53. Fawcett, L., Baxendaler, R., Stacey, P., Mcgrouther, C., Harrow, C., Soderling, et al. (2000). Molecular cloning and characterisation of a distinct human phosphodiesterase gene family: PDE11A. Proceedings of the National Academy of Science, 97, 3702-3707.
54. Feldman, H. A., Goldstein, I., Hatzichrisou, D. G., Krane, R. J., & McKinlay, J.P. (1994). Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. Journal of Urology, 151L, 54-61.
55. Feng, M. I., Huang, S., Kaptein, J., Kaswick, J., & Aboseif, S. (2000). Effect of sildenafil citrate on postradical prostatectomy erectile dysfunction. Journal of Urology, 164, 1935-1938.
56. Foreman, M. M., & Wernicke, J. F. (1990). Approaches for the development of oral drug therapies for erectile dysfunction. Seminars in Urology, 8, 107-112.
57. Gabrieli, C. B., Regine, F., Vingolo, E. M., Rispoli, E., Fabbri, A., & Isidori, A. (2001). Subjective visual halos after sildenafil (Viagra) administration: Electroretinographic evaluation. Ophthalmology, 108, 877-881.
58. Gingell, C., Jardin, A., Olsson, A. M., Martin, P., & Osterloh, I. and the Multicentre Study Group (1996). A new oral treatment for erectile dysfunction: A double-blind, placebo-controlled, once daily dose response study [Abstract 738]. Proceedings of the American Urological Association, 155(Suppl.), 495A.
59. Giuliano, F., Bernabe, J., Brown, K., Droupy, S., Benoit, G., & Rampin, O. (1997). Erectile response to hypothalamic stimulation in rats: Role of peripheral nerves. American Journal of Physiology, 273, R1990-1997.
60. Giuliano, F., Hultling, C., El Masry, W. S., Smith, M. D., Osterloh, I. H., Orr, M., & Maytom, M. (1999). Randomized trial for sildenafil for the treatment of erectile dysfunction in spinal cord injury. Annals of Neurology, 46, 15-21.
61. Giuliano, F., Meuleman, E., Saoud, J., Ferguson, K., Whitaker, S., & Porst, H. (2000). Daily IC351 treatment of erectile dysfunction. European Urology, 37(Suppl. 2), 80.
62. Goldstein, I., Lue, T., Padma-Nathan, H., Rosen, R., Steers, W., & Wicker, P. (1998). Oral sildenafil in the treatment of erectile dysfunction. New England Journal of Medicine, 338, 1397-1404.
63. Goldstein, I., Young, J. M., Fischer, J., Yuran, T., Taylor, T., and the Vardenafil Diabetes Phase III Study Group. (2001). Vardenafil improved erectile function in diabetic men with erectile dysfunction. International Journal of Impotence Research, 13(Suppl. 5). S65.
64. Guay, A. T., Perez, J. B., Jacobson, J., & Newton, R. A. (2001). Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. Journal of Andrology, 22, 793-797.
65. Herrmann, H. C., Chang, G., Klugherz, B. D., & Mahoney, P. D. (2000). Hemodynamic effects of sildenafil in men with severe coronary artery disease. New England Journal of Medicine, 342, 1622-1626.
66. Horowitz, A., Menice, C. B., Laporte R., & Morgan, K. G. (1996). Mechanisms of smooth muscle contraction. Physiology Reviews, 76, 967-1003.
67. Hoyle, C. H., Stones, R. W., Robson, T., Whitley, K., & Burnstock, G. (1996). Innervations of vasculature and microvasculature of the human vagina by NOS and neuropeptide-containing nerves. Journal of Anatomy, 188, 633-644.
68. Ignarro, L. (2001). Foreword. In L. Katzenstein, Viagra (sildenafil citrate): The remarkable story of the discovery and launch (p. iii). New York: Medical Information Press.
69. Ignarro, L. J., Cirini, G., Casini, A., & Napoli, C. J. (1999). Nitric oxide as a signaling molecule in the vascular system: An overview. Cardiovascular Pharmacology, 34, 879-886.
70. Islam, A., Mitchel, J. T., Hays, J., Rosen, R., & D'Agostino, R., Jr., (2001). Challenges in conducting multicenter clinical trials in female sexual dysfunction: Baseline differences between study populations. Journal of Sex & Marital Therapy 27, 525-530.
71. Jackson, G., Benjamin, N., Jackson, N., & Allen, M. J. (1999). Effects of sildenafil citrate on human hemodynamics. American Journal of Cardiology, 83(Suppl. 5A), 13C-20C.
72. Jardin, A., Wagner, G., Khoury, S., Giuliano, F., Padma-Nathan, H., & Rosen, R. (Eds.). (2000). Erectile dysfunction: 1st International Consultation on Erectile Dysfunction. Plymouth, UK: Health Publications.
73. Jarow, J. P., Burnett, A. L., & Geringer, A. M. (1999). Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. Journal of Urology, 162, 722-725.
74. Jones, M. J. (2001). Internet-based prescription of sildenafil: A 2104-patient series. Journal of Medical Internet Research, 3, E2.
75. Kaplan, S. A., Reis, R. B., Kohn, I. J., Ikeguchi, E. F., Laor, E., Te, A. E., & Martins, A. C. (1999). Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology, 53, 481-486.
76. Kassim, A. A., Fabry, M. E., & Nagel, R. L. (2000). Acute priapism associated with the use of sildenafil in a patient with sickle cell trait. Blood, 95, 1878-1879.
77. Katzenstein, L. (2001). Viagra (sildenafil citrate): The remarkable story of the discovery and launch. New York: Medical Information Press.
78. Kedia, S., Zippe, C. D., Agarwal, A., Nelson, D. R., & Lakin, M. M. (1999). Treatment of erectile dysfunction with sildenafil citrate (Viagra) after radiation therapy for prostate cancer. Urology, 54, 308-312.
79. Kim, N. N., Huang, Y. H., Goldstein, I., Bischoff, E., & Traish, A. M. (2001). Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. Life Science, 69, 2249-2256.
80. Klings, E. S., & Farber, H. W. (2001). Current management of primary pulmonary hypertension. Drugs, 61, 1945-1956.
81. Klotz, T., Sachse, R., Heidrich, A., Jockenhovel, F., Rohde, G., Wensing, G., et al. (2001). Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: A RigiScan and pharmacokinetic study. World Journal of Urology, 19, 32-39.
82. Koskimaki, J., Hakama, M., Huhtala, H., & Tammela, T. L. (2000). Effect of erectile dysfunction on frequency of intercourse: A population based prevalence study in Finland. Journal of Urology, 164, 367-370.
83. Krstic, R. V. (1997). Human microscopic anatomy. Berlin: Springer-Verlag.
84. Laan, E., Van Lunsen, R. H., Everaerd W., Riley, A., Scott, E., & Boolell, M. (2002). The enhancement of vaginal vasocongestion by sildenafil in healthy premenopausal women. Journal of Women's Health and Gender-Based Medicine, 11, 357-365.
85. Laumann, E. O., Paik, B. A., & Rosen, R. C. (1999). Sexual dysfunction in the United States: Prevalence, predictors, and outcomes. Journal of the American Medical Association, 281, 537-544.
86. Leiblum, S. R. (2002). After sildenafil: Bridging the gap between pharmacologic treatment and satisfying sexual relationships. Journal of Clinical Psychiatry, 63(Suppl. 5), 17-22.
87. Levin, R. J. (2002). The physiology of sexual arousal in the human female: A recreational and procreational synthesis. Archives of Sexual Behavior, 31, 405-412.
88. Lin, C. S., Lau, A., Tu, R., & Lue, T. F. (2000). Expression of three isoforms of cGMP-binding cGMP specific phosphodiesterases in human penile cavernosum. Biochemistry and Biophysics Research Communications, 268, 626-635.
89. Linet, O. J., & Ogrinc, F. G. (1996). Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. New England Journal of Medicine, 334, 873-877.
90. Loughney, K., Hill, T. R., Florio, V. A., Uher, L., Rosman, G. J., Wolda, S. L., et al. (1998) Isolation and characterization of cDNAs encoding PDE 5A, a human cGMP-binding, cGMP-specific 3', 5'-cyclic nucleotide phosphodiesterase. Gene, 216, 139-147.
91. Lowentritt, B. H., Scardino, P. T., Miles, B. J., Orejuela, F. J., Schatte, E. C., Slawin, K. M., et al., (1999). Sildenafil citrate after radical retropubic prostatectomy. Journal of Urology, 162, 1617-1619.
92. McDonald, L. J., & Murad, F. (1995). Nitric oxide and cGMP signaling. Advanced Pharmacology, 34, 263-75.
93. McDowell, A. J., Snellgrove, C. A., & Bond, M. J. (2001). Beyond Viagra. Psychological issues in the assessment and treatment of erectile dysfunction. Australian Family Physician, 30, 867-873.
94. McKinlay, J. B. (2001). The worldwide prevalence and epidemiology of erectile dysfunction. International Journal of Impotence Research, 13(Suppl. 4), S6-S11.
95. Meston, C. M., & Worcel, M. (2002). The effects of yohimbine plus L-arginine glutamate on sexual arousal in postmenopausal women with sexual arousal disorder. Archives of Sexual Behavior, 31, 323-332.
96. Meuleman, E., Cuzin, B., Opsomer, R. J., Hartmann, U., Bailey, M. J., Maytom, M. C., et al. (2001). A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. British Journal of Urology, 87, 75-81.
97. Montorsi, P., McDermott, T. E., Morgan, R., Olsson, A., Schultz, A., Kirkeby, H. J., & Osterloh, I.H. (1999). Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology, 53, 1011-1018.
98. Morales, A., Gingell, C., Collins, M., Wicker, P. A., & Osterloh, I. H. (1998). Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. International Journal of Impotence Research, 10, 69-74.
99. Moreira, S. G., Jr., Brannigan, R. E., Spitz, A., Orejuela, F. J., Lipshultz, L. I., & Kim, E. D. (2000). Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology, 56, 474-476.
100. Muller, M. J., & Benkert, O. (2001). Lower self-reported depression in patients with erectile dysfunction after treatment with sildenafil. Journal of Affective Disorders, 66, 255-261.
101. Muller, M. J., Ruof, J., Graf-Morgenstern, M., Porst, H., & Benkert, O. (2001). Quality of partnership in patients with erectile dysfunction after sildenafil treatment. Pharmacopsychiatry, 34, 91-95.
102. Nichols, D. J., Muirhead, G. J., & Harness, J. A. (2002). Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: Absolute bioavailability, food effects and dose proportionality. British Journal of Clinical Pharmacology, 53(Suppl. 1), 5S-12S.
103. Nurnberg, H. G., Gelenberg, A., Hargreave, T. B., Harrison, W. M., Siegel, R. L., & Smith, M. D. (2001). Efficacy of sildenafil citrate for the treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. American Journal of Psychiatry, 158, 1926-1928.
104. Nurnberg, H. G., Hensley, P. L., & Lauriello, J. (2000). Sildenafil in the treatment of sexual dysfunction induced by selective serotonin reuptake inhibitors - an overview. CNS Drugs, 13, 321-335.
105. Nurnberg, H. G., Hensley, P., & Laurillo, J. (2001). Sildenafil citrate for the treatment of sexual dysfunction associated with serotonergic reuptake inhibitors. International Journal of Impotence Research, 13, S49.
106. Nurnberg, H., Lauriello, J., Hensley, P., Parker, L., & Keith, S. (1999). Sildenafil for iatrogenic serotonergic antidepressant medication-induced sexual dysfunction in 4 patients. Journal of Clinical Psychiatry, 60, 33-35.
107. Nurnberg, H. G., Seidman, S. N., Gelenberg, A. J., Fava, M., Rosen, R., & Shabsigh, R. (2002). Depression, antidepressant therapies and erectile dysfunction: Clinical trials of sildenafil citrate in treated and untreated patients with depression. Urology, 60(Suppl. 2B), 58-62.
108. Olsson, A. M., & Persson, C-A. (2001). Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. International Journal of Clinical Practice, 55, 171-176.
109. Padma-Nathan, H. (2002). Efficacy and tolerability of tadalafil, a novel PDE-5 inhibitor, in treatment of men with erectile dysfunction. American Journal of Cardiology (in press).
110. Padma-Nathan, H., Hellstrom, W. J., Kaiser, F. E., Labasky, R. C., Lue, T., Nolton, W. E., et al. (1997). Treatment of men with erectile dysfunction with transurethral alprostadil. New England Journal of Medicine, 336, 1-7.
111. Padma-Nathan, H., McMurray, J. G., Pullman, W. E., Whitaker, J. S., Saoud, J. B., Ferguson, K. M., & Rosen, R. C. (2001). On demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. International Journal of Impotence Research, 13, 2-9.
112. Padma-Nathan, H., Rosen, R. C., Shabsigh, R., Saikali, K., Watkins, V., & Pullman, B. (2001, June 2-7). IC351 (Cialis') provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction (ED). Paper presented at the 96th Annual Meeting of the American Urological Association, Anaheim, CA.
113. Paige, N. M., Hays, R. D., Litwin, M. S., Rajfer, J., & Shapiro, M. F. (2001). Improvement in emotional well being and relationships of users of sildenafil. Journal of Urology, 166, 1774-1778.
114. Pallas, J., Levine, S., Althof, S., & Risen, C. (1999, March 5). A prospective study of the use of Viagra in a mental health professionals' practice. Paper presented at the Society for Sex Therapy and Research, Boston, MA.
115. Podlasek, C. A., Gonzalez, C. M., Zelner, D., Jiang, H. B., McKenna, K. E., & McVary, K. T. (2001). Analysis of NOS isoform changes in a post radical prostatectomy model of erectile dysfunction. International Journal of Impotence Research, 13(Suppl. 5), S1-S15.
116. Pomeranz, H. D., Smith, K. H., Hart, W. M., Jr., & Egan, R. A. (2002). Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology, 109, 584-587.
117. Porst, H. (2002). IC351 (tadalafil, Cialis): Update on clinical experience. International Journal of Impotence Research, 14(Suppl. 2), S57-S64.
118. Porst, H., Rosen, R., Padma-Nathan, H., Goldstein, I., Giuliano, F., Ulbrich, E., & Bandel, T. (2001). The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial. International Journal of Impotence Research, 13, 192-199.
119. Porst, H., Rosen, R. C., Padma-Nathan, H., Varanese, L., Anglin, G., & Giuliano, F. (2002). Tadalafil allows men with erectile dysfunction to have successful intercourse up to 36 hours postdose. Journal of Urology, 167(Suppl. 4), 177.
120. Rendell, M. S., Rajfer, J., Wicker, P., & Smith, M. (1999). Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial. Journal of the American Medical Association, 281, 421-426.
121. Rhee, P. L., Hyun, J. G., Lee, J. H., Kim, Y. H., Son, J. J., Paik, S. W., et al. (2001). The effect of sildenafil on lower esophageal sphincter and body motility in normal male adults. American Journal of Gastroenlerology. 96, 3251-3257.
122. Rosen, R. C. (2000). Management of complicated and treatment-refractory ED: Clinical issues and guidelines. International Journal of Impotence Research, 12, 59-60.
123. Rosen, R. C. (2002). Sexual function assessment and the role of vasoactive drugs in female sexual dysfunction. Archives of Sexual Behavior, 31, 439-444.
124. Rosen, R. C., & Ashton, A. K. (1993). Prosexual drugs: Empirical status of the "new aphrodisiacs." Archives of Sexual Behavior, 22, 521-543.
125. Rosen, R., Bennett, A., Ferguson, D., Hirsch, M., Padma-Nathan, H., & Wyllie, M. (2000). Standards for clinical trials in erectile dysfunction: Research designs and outcomes assessment. In A. Jardin, G. Wagner, S. Khoury, F. Giuliano, H. Padma-Nathan, & R. C. Rosen (Eds). Erectile dysfunction (pp. 647-678). Plymouth, UK: Health Publications.
126. Rosen, R. C., Cappelleri, J. C., & Gendrano, N. (2002). The International Index of Erectile Function (IIEF): A state-of-the-science review. International Journal of Impotence Research, 14, 226-244.
127. Rosen, R. C., & Kostis, J. B. (in press). Phosphodiesterase type 5 (PDE5) inhibition in erectile dysfunction. American Journal of Cardiology.
128. Rosen, R., Lane, R., & Menza, M. (1999). Effects of SSRIs n sexual function: A critical review. Journal of Clinical Psychopharmacology, 19, 67-85.
129. Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997). The International Index of Erectile Function(IIEF): A Multidimensional Scale for Assessment of Erectile Dysfunction. Urology, 49, 822-830.
130. Rotella, D. P. (2001). Phosphodiesterase type 5 inhibitors: Discovery and therapeutic utility. Drugs of the Future, 26, 153-162.
131. Rybalkin, S. D., Rybalkin, I. G., Feil, R., Hofmann, F., & Beavo, J. A. (2002). Regulation of cAMP-specific phosphodiesterase (PDE 5) phosphorylation in smooth muscle cells. Journal of Biological Chemistry, 277, 3310-3317.
132. Sáenz de Tejada I., Angulo J., Cuevas P., Fernandez A., Moncada I., Allona, A., et al. (2001). The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE-5 inhibitor vardenafil. International Journal of Impotence Research, 13, 282-290.
133. Sáenz de Tejada, I., Emmick, J., Anglin, G., Fredlund, P., & Pullman, W. E. (2001, April 7-10). The effect of IC351 taken as needed for treatment of erectile dysfunction in men with diabetes. Poster session presented at the 16th Congress of the European Association of Urology, Geneva, Switzerland.
134. Sanchez, R. A., Vidai, J., Jauregui, M. L., Barrera, M., Recio, C., Giner, M., et al. (2001). Efficacy, safety and predictive factors of therapeutic success with sildenafil for erectile dysfunction in patients with different spinal cord injuries. Spinal Cord, 39, 637-643.
135. Schaller, J. L., & Behar, D. (1999). Sildenafil citrate for SSRI-induced sexual side effects. American Journal of Psychiatry, 156, 156-157.
136. Seidman, S. N., & Roose, S. P. (2000). The relationship between depression and erectile dysfunction. Current Psychiatry Reports, 2, 201-205.
137. Seidman, S. N., Roose, S. P., Menza, M. A., Shabsigh, R., & Rosen, R. C. (2001). Treatment of erectile dysfunction in men with depressive symptoms: Results of a placebo-controlled trial with sildenafil citrate. American Journal of Psychiatry, 158, 1623-1630.
138. Seidman, S. N., Roose, S. P., & Rosen, R. C. (in press). Psychiatric disorders and sexual function. In D. Charney (Ed.), The neurobiology of mental illness.
139. Sipski, M. L., Rosen, R. C., Alexander, C. J., & Hamer, R. M. (2000). Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. Urology, 55, 812-815.
140. Stacey, P., Rulten, S., Dapling, A., & Phillips, S. C. (1998). Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE 5). Biochemistry and Biophysics Research Communications, 247, 249-254.
141. Steidle, C., Porst, H., Hollister, A., & Segerson, T. (2001). Vardenafil demonstrated similar efficacy and tolerability among older and younger patients with marginal differences in PK characteristics between age groups. International Journal of Impotence Research, 13(Suppl. 5), S63.
142. Stark, S., Sachse, R., Liedl, T., Hensen, J., Rohde, G., Wensing, G., et al. (2001). Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. European Urology, 40, 181-190.
143. Sur, R. L., & Kane, C. J. (2000). Sildenafil citrate-associated priapism. Urology, 55, 950.
144. Tan, H. M., Moh, C. L., Mendoza, J. B., Gana, T., Albano, G. J., de la Cruz, R., et al. (2000). Asian sildenafil efficacy and safety study: A double-blind, placebo controlled, flexible dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. The Assess-1 study Group. Urology, 56, 635-640.
145. Tiefer, L. (2000). The medicalization of women's sexuality. American Journal of Nursing, 100(12), 11.
146. Traish, A. M., Kim, N. N., Min, K., Munarriz, R., & Goldstein, I. (2002). Role of androgens in female genital arousal: Receptor expression, structure and function. Fertility and Sterility, 77(Suppl. 4), 11-18.
147. Traish, A. M., Kim, N. N., Munarriz, R., Moreland, R., & Goldstein, I. (2002). Biochemical and physiological mechanisms of female genital arousal. Archives of Sexual Behavior, 31, 393-400.
148. Turko, I. V., Ballard, S. A., Francis, S. H., & Corbin, J. D. (1999). Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Molecular Pharmacology, 56, 124-130.
149. Uckert, S., Kuthe, A., Stief, C. G., & Jonas, U. (2001). Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World Journal of Urology, 19, 14-22.
150. Vemulapalli, S., & Kurowski, S. Sildenafil relaxes rabbit clitoral corpus cavernosum. (2000). Life Science, 67, 23-29.
151. Waldinger, M. D., Hengeveld, M. W., & Zwinderman, A. H. (1998). Effect of SSRI antidepressants on ejaculation: A double-blind, randomized, placebo-controlled study. Journal of Clinical Psychopharmacology, 18, 274-281.
152. Walker, D. K., Ackland, M. J., James, G. C., Muirhead, G. J., Rance, D. J., Wastall, P., & Wright, P. A. (1999). Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica, 29, 297-310.
153. Wallis, R. M. (1999). The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5. Nippon Yakurigaku Zasshi, 114(Suppl. 1), 22P-26P.
154. Wallis, R. M., Corbin, J. D., Francis, S. H., & Ellis, P. (1999). Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. American Journal of Cardiology, 83, 3C-12C.
155. Webb, D. J., Muirhead, G. J., Wulff, M., Sutton, J. A., Levi, R., & Dinsmore, W. W. (2000). Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. Journal of the American College of Cardiology, 36, 25-31.
156. Weeks, G. R., & Gambescia, N. (2000). Erectile dysfunction: Integrating couple therapy, sex therapy and medical treatment. New York: Norton and Company.
157. Wise, T. N. (1999). Psychosocial side effects of sildenafil therapy for erectile dysfunction, Journal of Sex and Marital Therapy, 25, 145-150.
158. Ziessen, T., Moncada, S., & Cellek, S. (2002). Characterization of the nonnitrergic NANC relaxation responses in the rabbit vaginal wall. British Journal of Pharmacology, 135, 546-554.
159. Zippe, C. D., Jhaveri, F. M., Klein, E. A., Kedia, S., Pasqualott, F. F., Kedia, A., et al. (2000). Role of viagra after radical prostatectomy. Urology, 55, 241-245.
160. Zusman, R. M., Morales, A., Glasser, D. B., & Osterloh, I. H. (1999). Overall cardiovascular profile of sildenafil citrate. American Journal of Cardiology, 83, 35C-44C.